Adicet Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $57.9M
- Price
- $6.18
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.12%
- Volume
- 214.3K
About
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding9.4M
Computed float9.3M
Float / shares99.7%
Cash runway (months)13.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001720580
Websitehttps://www.adicetbio.com
AI Summary
AI-generated1/22
minorneutralother
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio granted a Nasdaq Rule 5635(c)(4) inducement award of 725 non-qualified stock options to one newly hired employee, with a $7.14 exercise price equal to the September 30, 2026 closing price.
The award was made under the 2022 Inducement Plan outside stockholder-approved plans and authorized by the independent-director compensation committee.
The grant is routine equity compensation with no bearing on the company's clinical pipeline or financials.